These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 32818555)

  • 41. Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.
    Marchetti M; Barosi G; Cervantes F; Birgegård G; Griesshammer M; Harrison C; Hehlmann R; Kiladjian JJ; Kröger N; McMullin MF; Passamonti F; Vannucchi A; Barbui T
    Leukemia; 2017 Apr; 31(4):882-888. PubMed ID: 27740634
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Ruxolitinib as a bridge to allogeneic hematopoietic cell transplantation in a patient with idiopathic myelofibrosis].
    Barba P; Fox ML; Blanco A; Valcárcel D
    Med Clin (Barc); 2015 Feb; 144(4):184-5. PubMed ID: 24952663
    [No Abstract]   [Full Text] [Related]  

  • 43. Rationale for combination therapy in myelofibrosis.
    Mascarenhas J
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):197-208. PubMed ID: 25189730
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of ruxolitinib for myelofibrosis.
    Santos FP; Verstovsek S
    Expert Opin Pharmacother; 2014 Jul; 15(10):1465-73. PubMed ID: 24856675
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?
    Breccia M; Molica M; Colafigli G; Alimena G
    Expert Rev Hematol; 2015 Aug; 8(4):387-9. PubMed ID: 25915176
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
    Lancman G; Mascarenhas J
    Expert Rev Hematol; 2017 Jan; 10(1):23-28. PubMed ID: 27882812
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Myelofibrosis-When Do We Select Transplantation or Non-transplantation Therapeutic Options?
    Viswabandya A; Devlin R; Gupta V
    Curr Hematol Malig Rep; 2016 Feb; 11(1):6-11. PubMed ID: 26659587
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Ruxolitinib for treatment of GvHD in patients with myelofibrosis].
    Mori Y
    Rinsho Ketsueki; 2019; 60(8):953-959. PubMed ID: 31484895
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation.
    Kröger N; Shahnaz Syed Abd Kadir S; Zabelina T; Badbaran A; Christopeit M; Ayuk F; Wolschke C
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2152-2156. PubMed ID: 29800615
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
    Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Raza A; Vaddi K; Sun W; Peng W; Sandor V; Kantarjian H;
    Haematologica; 2015 Apr; 100(4):479-88. PubMed ID: 25616577
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Isolated Nodal TBC Reactivation in a Patient with Post-Thrombocythemia Myelofibrosis Treated with Ruxolitinib: Case Report and Review of the Literature.
    Santoro M; Rotolo C; Accurso V; Morreale I; Mancuso S; Siragusa S
    Chemotherapy; 2021; 66(3):87-91. PubMed ID: 33784668
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
    Verstovsek S; Mesa RA; Gotlib J; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Paquette R; Raza A; Jones M; Kornacki D; Sun K; Kantarjian H;
    J Hematol Oncol; 2017 Feb; 10(1):55. PubMed ID: 28228106
    [TBL] [Abstract][Full Text] [Related]  

  • 53. How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes.
    Massaro F; Molica M; Breccia M
    Expert Rev Hematol; 2017 Feb; 10(2):155-159. PubMed ID: 27983880
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ruxolitinib: a new treatment option for myelofibrosis.
    Ganetsky A
    Pharmacotherapy; 2013 Jan; 33(1):84-92. PubMed ID: 23307549
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
    Pugliese N; Giordano C; Nappi D; Luciano L; Cerchione C; Annunziata M; Casale B; Crisà E; Villa MR; Pezzullo L; Iovine M; Picardi M; Grimaldi F; Pane F; Martinelli V
    Cancer Med; 2019 Jun; 8(6):2802-2809. PubMed ID: 30997748
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimizing the management of patients with myelofibrosis.
    Manea PJ
    Clin J Oncol Nurs; 2014 Jun; 18(3):330-7. PubMed ID: 24867113
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recommendations on the use of ruxolitinib for the treatment of myelofibrosis.
    Devos T; Selleslag D; Zachée P; Benghiat FS
    Hematology; 2018 May; 23(4):194-200. PubMed ID: 29022420
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
    Mesa RA; Gotlib J; Gupta V; Catalano JV; Deininger MW; Shields AL; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Hare T; Erickson-Viitanen S; Sun W; Sandor V; Levy RS; Kantarjian HM; Verstovsek S
    J Clin Oncol; 2013 Apr; 31(10):1285-92. PubMed ID: 23423753
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
    Breccia M; Andriani A; Montanaro M; Abruzzese E; Buccisano F; Cedrone M; Centra A; Villivà N; Celesti F; Trawinska MM; Massaro F; Di Veroli A; Anaclerico B; Colafigli G; Molica M; Spadea A; Petriccione L; Cimino G; Latagliata R
    Ann Hematol; 2017 Mar; 96(3):387-391. PubMed ID: 27889820
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management.
    Krauth MT; Burgstaller S; Buxhofer-Ausch V; Gastl G; Geissler K; Keil F; Krippl P; Melchardt T; Petzer A; Rumpold H; Sliwa T; Wöhrer S; Wölfler A; Gisslinger H
    Wien Klin Wochenschr; 2018 Sep; 130(17-18):495-504. PubMed ID: 30043249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.